CL2011000084A1 - Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende. - Google Patents

Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende.

Info

Publication number
CL2011000084A1
CL2011000084A1 CL2011000084A CL2011000084A CL2011000084A1 CL 2011000084 A1 CL2011000084 A1 CL 2011000084A1 CL 2011000084 A CL2011000084 A CL 2011000084A CL 2011000084 A CL2011000084 A CL 2011000084A CL 2011000084 A1 CL2011000084 A1 CL 2011000084A1
Authority
CL
Chile
Prior art keywords
hcmv
understands
encodes
binds
vector
Prior art date
Application number
CL2011000084A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Inst Res Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Res Biomedicine filed Critical Inst Res Biomedicine
Publication of CL2011000084A1 publication Critical patent/CL2011000084A1/es
Priority to CL2014001293A priority Critical patent/CL2014001293A1/es
Priority to CL2016001340A priority patent/CL2016001340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2011000084A 2008-07-16 2011-01-14 Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende. CL2011000084A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2014001293A CL2014001293A1 (es) 2008-07-16 2014-05-16 Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
CL2016001340A CL2016001340A1 (es) 2008-07-16 2016-06-01 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos (divisional de sol. n° 1293-14, la cual es a su vez, divisional de sol. n° 84-11).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16

Publications (1)

Publication Number Publication Date
CL2011000084A1 true CL2011000084A1 (es) 2011-07-01

Family

ID=41550776

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2011000084A CL2011000084A1 (es) 2008-07-16 2011-01-14 Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende.
CL2014001293A CL2014001293A1 (es) 2008-07-16 2014-05-16 Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
CL2016001340A CL2016001340A1 (es) 2008-07-16 2016-06-01 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos (divisional de sol. n° 1293-14, la cual es a su vez, divisional de sol. n° 84-11).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2014001293A CL2014001293A1 (es) 2008-07-16 2014-05-16 Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
CL2016001340A CL2016001340A1 (es) 2008-07-16 2016-06-01 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos (divisional de sol. n° 1293-14, la cual es a su vez, divisional de sol. n° 84-11).

Country Status (30)

Country Link
US (21) US8603480B2 (OSRAM)
EP (3) EP2352759B1 (OSRAM)
JP (5) JP5422649B2 (OSRAM)
KR (1) KR101356350B1 (OSRAM)
CN (3) CN106924729B (OSRAM)
AU (1) AU2009272284C1 (OSRAM)
BR (1) BRPI0916443A2 (OSRAM)
CA (2) CA3022196A1 (OSRAM)
CL (3) CL2011000084A1 (OSRAM)
CO (1) CO6351801A2 (OSRAM)
CR (2) CR20160355A (OSRAM)
CU (1) CU23953B1 (OSRAM)
DK (2) DK2352759T3 (OSRAM)
EA (1) EA031177B1 (OSRAM)
EC (2) ECSP11010826A (OSRAM)
ES (2) ES2682596T3 (OSRAM)
GT (4) GT201100011DA (OSRAM)
HN (1) HN2011000161A (OSRAM)
IL (7) IL210356A (OSRAM)
MA (1) MA32561B1 (OSRAM)
MX (5) MX2011000543A (OSRAM)
NZ (5) NZ603499A (OSRAM)
PE (7) PE20141434A1 (OSRAM)
PH (1) PH12015500782A1 (OSRAM)
PL (2) PL2352759T3 (OSRAM)
PT (2) PT2352759T (OSRAM)
SG (3) SG10201706350PA (OSRAM)
UA (1) UA106354C2 (OSRAM)
WO (1) WO2010007533A2 (OSRAM)
ZA (1) ZA201600335B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CA3022196A1 (en) 2008-07-16 2010-01-21 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
NZ600974A (en) 2009-12-23 2014-08-29 4Antibody Ag Binding members for human cytomegalovirus
KR101900435B1 (ko) 2010-06-16 2018-09-20 트렐리스 바이오싸이언스 인코포레이티드 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
PL3243526T3 (pl) 2010-07-06 2020-05-18 Glaxosmithkline Biologicals S.A. Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
HUE061068T2 (hu) 2010-08-31 2023-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS szállítására
KR20130112879A (ko) * 2010-09-29 2013-10-14 제넨테크, 인크. 항체 조성물 및 사용 방법
EP4098324A1 (en) * 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
HK1206759A1 (en) * 2012-03-28 2016-01-15 F. Hoffmann-La Roche Ag Anti-hcmv idiotypic antibodies and uses thereof
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
WO2017044895A2 (en) 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
CN105296588A (zh) * 2015-10-16 2016-02-03 常州市第一人民医院 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3016867A1 (en) 2016-03-11 2017-09-14 Pfizer Inc. Human cytomegalovirus gb polypeptide
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
EP3445393A4 (en) 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
WO2017196819A2 (en) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
EP3497232A1 (en) 2016-08-12 2019-06-19 Streck, Inc. Molecular reference controls
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
US11484570B2 (en) 2017-04-14 2022-11-01 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
ES3036734T3 (en) 2017-04-19 2025-09-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
CA3079415A1 (en) 2017-10-19 2019-04-25 Streck, Inc. Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CA3060547A1 (en) 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
JP7584405B2 (ja) 2018-10-17 2024-11-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変されたサイトメガロウイルスタンパク質及び安定化された複合体
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020208082A1 (en) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US20230174626A1 (en) * 2020-03-27 2023-06-08 Glaxosmithkline Biologicals Sa Antibodies
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
CN116162154B (zh) * 2022-10-21 2024-06-11 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) * 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) * 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) * 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986002092A1 (fr) 1984-09-28 1986-04-10 Teijin Limited Hybridome homme-souris produisant un anticorps humain antiviral, procede de preparation et anticorps monoclonal humain antiviral
US4808518A (en) * 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) * 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0248909B1 (en) 1985-12-06 1994-08-17 Teijin Limited Anticytomegaloviral human monoclonal antibody and process for its preparation
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US5180813A (en) * 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
DE69227623T2 (de) 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
AU681115B2 (en) 1993-01-21 1997-08-21 Erna Moller Prevention and treatment of cytomegalovirus using aminopeptidase
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
CA2153790A1 (en) 1993-01-28 1994-08-04 Lars G. Ostberg Human monoclonal antibodies to cytomegalovirus
WO1994025490A1 (en) 1993-04-30 1994-11-10 The Scripps Research Institute Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) * 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
EP0960336B1 (en) 1996-07-12 2002-10-09 Organon Teknika B.V. Peptide reagent for the detection of human cytomegalovirus (cmv)
AU728285C (en) 1996-08-14 2002-02-21 Wistar Institute Of Anatomy And Biology, The Methods and compositions for preventing or retarding the development of atherosclerotic lesions
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
US6156498A (en) 1997-01-30 2000-12-05 Cedars-Sinai Medical Center Establishment of HHV-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting HHV-8 infection
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
CN1174099C (zh) 1997-07-18 2004-11-03 康诺特实验室有限公司 编码呼吸道合胞病毒的g蛋白的核酸疫苗
BR9815285A (pt) 1997-11-14 2001-11-13 Connaught Lab Vetores alfavìrus para vacina de paramixovìrus
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
EP1061943B1 (en) 1998-03-12 2002-10-23 Genentech, Inc. Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
ATE249846T1 (de) 1998-06-29 2003-10-15 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2002247733B2 (en) 2001-02-21 2007-12-13 The Wistar Institute Of Anatomy And Biology Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
CN1188427C (zh) * 2001-12-07 2005-02-09 暨南大学 检测hcmv抗体的重组嵌合肽抗原及其产生方法
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
CA2480811A1 (en) 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (ru) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) * 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
EP1778862A2 (en) 2004-07-09 2007-05-02 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Differences in intestinal gene expression profiles
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
JP4884395B2 (ja) 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
DE602005027258D1 (de) 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
ES2360232T3 (es) 2005-06-29 2011-06-02 Compumedics Limited Conjunto sensor con puente conductor.
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
US8338172B2 (en) 2005-12-16 2012-12-25 Ribovax Biotechnologies S.A. Methods for obtaining immortalized antibody secreting cells
JPWO2007094423A1 (ja) * 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
ZA200810677B (en) 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
JP5822433B2 (ja) * 2006-06-07 2015-11-24 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8153129B2 (en) 2006-12-15 2012-04-10 Ribovax Biotechnologies S.A. Antibodies against human cytimegalovirus (HCMV)
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) * 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
WO2009024445A1 (en) 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hcmv)
WO2009085383A1 (en) 2007-12-19 2009-07-09 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
AU2008359583B2 (en) 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
CA3022196A1 (en) 2008-07-16 2010-01-21 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof

Also Published As

Publication number Publication date
US9221897B2 (en) 2015-12-29
US8124093B2 (en) 2012-02-28
US20140193428A1 (en) 2014-07-10
MX343490B (es) 2016-11-08
US20130022618A1 (en) 2013-01-24
US20120128691A1 (en) 2012-05-24
SG10201706350PA (en) 2017-09-28
US20200017575A1 (en) 2020-01-16
CN106924729A (zh) 2017-07-07
CN103980363B (zh) 2017-04-12
PE20141435A1 (es) 2014-10-22
IL238421A0 (en) 2015-06-30
IL232862A0 (en) 2014-07-31
JP6703037B2 (ja) 2020-06-03
GT201100011CA (es) 2017-09-14
JP2014087337A (ja) 2014-05-15
ZA201600335B (en) 2017-11-29
NZ591056A (en) 2013-02-22
WO2010007533A3 (en) 2010-08-12
IL232864A (en) 2016-07-31
IL210356A0 (en) 2011-03-31
MX343250B (es) 2016-10-31
GT201100011BA (es) 2017-09-14
IL232861A0 (en) 2014-07-31
US9796771B2 (en) 2017-10-24
JP6345753B2 (ja) 2018-06-20
IL238421A (en) 2016-06-30
CA3022196A1 (en) 2010-01-21
US8298539B2 (en) 2012-10-30
HK1220981A1 (en) 2017-05-19
BRPI0916443A2 (pt) 2017-10-31
US20100092481A1 (en) 2010-04-15
US10889632B2 (en) 2021-01-12
PE20141434A1 (es) 2014-10-22
DK3009449T3 (en) 2018-08-06
US9725502B2 (en) 2017-08-08
JP6062477B2 (ja) 2017-01-18
PT2352759T (pt) 2018-01-08
CU23953B1 (es) 2013-10-29
IL232863A (en) 2016-06-30
MX2011000543A (es) 2011-04-27
NZ707788A (en) 2016-08-26
JP2011527902A (ja) 2011-11-10
US20140205615A1 (en) 2014-07-24
EA201170205A1 (ru) 2011-08-30
US20170129940A1 (en) 2017-05-11
PE20141433A1 (es) 2014-10-19
US8435524B2 (en) 2013-05-07
UA106354C2 (ru) 2014-08-26
PH12015500782A1 (en) 2015-12-14
WO2010007533A9 (en) 2017-08-10
PL2352759T3 (pl) 2018-04-30
PE20140882A1 (es) 2014-07-25
US8287870B2 (en) 2012-10-16
US20150353627A1 (en) 2015-12-10
GT201100011AA (es) 2017-09-14
CU20110009A7 (es) 2012-06-21
IL210356A (en) 2015-06-30
ECSP11010827A (es) 2011-07-29
IL232865A (en) 2016-07-31
JP5422649B2 (ja) 2014-02-19
CR20160355A (es) 2016-10-11
JP5807050B2 (ja) 2015-11-10
US10414817B2 (en) 2019-09-17
US9527902B2 (en) 2016-12-27
PT3009449T (pt) 2018-09-28
IL232862A (en) 2016-06-30
EP3178845A1 (en) 2017-06-14
US9803000B1 (en) 2017-10-31
CA2730776A1 (en) 2010-01-21
US20110268746A1 (en) 2011-11-03
MA32561B1 (fr) 2011-08-01
NZ619953A (en) 2015-06-26
CL2016001340A1 (es) 2016-10-28
HN2011000161A (es) 2014-06-09
AU2009272284B2 (en) 2012-04-05
PE20141398A1 (es) 2014-10-18
CA2730776C (en) 2018-12-11
CN103980363A (zh) 2014-08-13
KR101356350B1 (ko) 2014-01-27
IL232861A (en) 2016-06-30
CO6351801A2 (es) 2011-12-20
MX340315B (es) 2016-07-06
US9796772B2 (en) 2017-10-24
US20170334972A1 (en) 2017-11-23
US9491906B2 (en) 2016-11-15
SG10201608381SA (en) 2016-11-29
EP3009449A1 (en) 2016-04-20
US20180371062A1 (en) 2018-12-27
US20170129939A1 (en) 2017-05-11
IL232864A0 (en) 2014-07-31
KR20110052585A (ko) 2011-05-18
US9371372B2 (en) 2016-06-21
NZ603499A (en) 2014-05-30
US20160145319A1 (en) 2016-05-26
DK2352759T3 (en) 2017-12-18
CN102203133B (zh) 2015-01-07
EA031177B1 (ru) 2018-11-30
CN102203133A (zh) 2011-09-28
US20170081391A1 (en) 2017-03-23
US8603480B2 (en) 2013-12-10
US10040845B2 (en) 2018-08-07
JP2015145412A (ja) 2015-08-13
NZ603498A (en) 2014-02-28
MX338067B (es) 2016-04-01
CN106924729B (zh) 2021-03-02
EP2352759B1 (en) 2017-11-01
EP3009449B1 (en) 2018-06-06
US20160280770A1 (en) 2016-09-29
JP2018139611A (ja) 2018-09-13
IL232865A0 (en) 2014-07-31
EP2352759A2 (en) 2011-08-10
US20160096880A1 (en) 2016-04-07
US20130302350A1 (en) 2013-11-14
GT201100011DA (es) 2017-09-20
ES2682596T3 (es) 2018-09-21
PE20110413A1 (es) 2011-06-25
US9249213B2 (en) 2016-02-02
US20210087257A1 (en) 2021-03-25
PL3009449T3 (pl) 2018-09-28
AU2009272284A1 (en) 2010-01-21
CR20110091A (es) 2011-06-24
AU2009272284C1 (en) 2014-05-15
WO2010007533A2 (en) 2010-01-21
ES2654543T3 (es) 2018-02-14
US20180086819A1 (en) 2018-03-29
CL2014001293A1 (es) 2014-12-05
SG191699A1 (en) 2013-07-31
US20120128692A1 (en) 2012-05-24
IL232863A0 (en) 2014-07-31
US9127049B2 (en) 2015-09-08
JP2017055765A (ja) 2017-03-23
ECSP11010826A (es) 2011-07-29
PE20141432A1 (es) 2014-10-18
US8765132B2 (en) 2014-07-01
US9365636B1 (en) 2016-06-14
US20160280769A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CL2011000084A1 (es) Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende.
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2013002040A1 (es) Anticuerpo biespecifico o fragmento del mismo que se une especificamente a il-13 e il-14; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica; y sus usos (div.sol.n°3037-08).
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2012002662A1 (es) Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico.
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
CL2011002304A1 (es) Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CL2008001887A1 (es) Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2014001055A1 (es) Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
CL2013002623A1 (es) Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.
CL2013001625A1 (es) Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
CL2012003093A1 (es) Anticuerpo aislado multivalente que tiene al menos dos dominios de union a receptores para dos diferentes sitios de union de un receptor diana lrp6 que inhiben una via canonica de transduccion de señal wnt; anticuerpo aislado biparatopico que une lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; metodo de obtencion de dicho anticuerpo; y su uso para tratar cancer.
CL2011001285A1 (es) Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
CL2015001709A1 (es) Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido.
WO2008115504A3 (en) Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
BRPI1005984A2 (pt) anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.